Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2016.5235

OL-0-0-5235

Articles

HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method

Sharifi

Nazanin

1 * Salmaninejad

Arash

1 2 * Ferdosi

Samira

1 Bajestani

Abolfazl Nesaei

3 Khaleghiyan

Malihe

1 4 Estiar

Mehrdad Asghari

4 Jamali

Mansour

5 Nowroozi

Mohammad Reza

6 Shakoori

Abbas

1 4

1Department of Medical Genetics, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran 1419733141, Iran 2Genetic Research Center, Student Research Committee, Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran 3Department of Medical Genetics, Ayatollah Madani Hospital, Gonabad University of Medical Sciences, Gonabad 9698154813, Iran 4Department of Medical Genetics, Tehran University of Medical Sciences, Tehran 1471613151, Iran 5Department of Pathology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran 1471613151, Iran 6Uro Oncology Research Center, Tehran University of Medical Sciences, Tehran 1471613151, Iran

Correspondence to: Dr Abbas Shakoori, Department of Medical Genetics, Cancer Institute of Iran, Tehran University of Medical Sciences, Keshavarz Blvd, Poursina Street, Tehran 1419733141, Iran, E-mail: shakooria@tums.ac.ir *

Contributed equally

12 2016

10 10 2016

12 6 4651 4658 04122015 12072016

2016

Prostate cancer (PCa) is one of the most widespread malignancies in the world. The role of the human epidermal growth factor receptor 2 (HER2) in the pathogenesis and progression of human PCa remains poorly understood. In contradiction with breast cancer, studies on HER2 overexpression and gene amplification in PCa have produced varying results, although the HER2 oncogene has been implicated in the biology of numerous tumor types, and serves as a prognostic marker and therapeutic target in breast cancer. Technical challenges are considered the main reasons for data discrepancies. Amplification of the HER2 gene has previously been reported in PCa, in which it was associated with tumor progression. The present study aimed to evaluate the prevalence and clinical significance of HER2 amplification in PCa. A total of 32 biopsy samples obtained from human prostate adenocarcinomas were evaluated by chromogenic in situ hybridization (CISH) to determine the frequency of patients with HER2 gene amplifications. High copy numbers of HER2 were detected in 19 of the prostate tumors analyzed. The results of the present study suggested that, in patients without amplification of HER2, high levels of prostate-specific antigen or a high Gleason score were not significantly correlated with a high pathologic stage. Furthermore, amplification levels of the HER2 gene were directly associated with pathologic stage in patients with PCa. Therefore, the potential use of HER2 as a prognostic factor or therapeutic target for PCa warrants further study.

prostate cancer human epidermal growth factor receptor 2 amplification gene chromogenic in situ hybridization

Introduction

Prostate cancer (PCa), a common non-skin, sex-limited cancer, is the second cause of cancer-associated mortality (after lung cancer) in the USA (1,2) and the second most prevalent cancer among Iranian men (3). Worldwide, PCa is the second most commonly diagnosed cancer and, according to the International Agency for Research on Cancer's GLOBOCAN 2012 (4) database, it is the fifth leading cause of cancer-associated mortality in men. The incidence of PCa is increasing worldwide, although there is a marked variation in its incidence among different regions (5). The clinical configuration of PCa has noticeably altered over the past few years. As a localized disease, it is easily treated by radical radiation therapy or a prostatectomy; however, if the tumor becomes malignant, it transforms into a life-threatening disease (6).

The progression and application of novel high-resolution technologies has enhanced the detection of genomic alterations, enabling elucidation of the complex nature and heterogeneity of PCa (7). The differentiation of PCa tumors is typically based on the serum expression levels of prostate-specific antigen (PSA), although, in certain cases, PSA levels do not accurately reflect tumor burden (8). Previous studies have identified a number of genetic, epigenetic and environmental risk factors for PCa (9–11). Among them, genetic aberrations and chromosomal changes have been suggested to serve a significant role in the development and progression of PCa (12). At present, >50 PCa susceptibility loci have been identified using genome-wide association studies (13,14). The emerging picture of the genomic complexity of PCa includes frequent large-scale genomic rearrangements (15), gene fusions (16,17), genetic deletions (15) and gene amplifications (18).

Gene amplification, which may occur due to an increase in copy number of certain regions of chromosomes, has been identified in several malignancies, including PCa (18,19). Previous studies have reported that the genetic duplication of various genes was associated with PCa malignancy, including androgen receptor (20), enhancer of zeste homolog 2 (21), eukaryotic translation initiation factor 3 (22), calcium-activated potassium channel subunit α-1 (23), minichromosome maintenance complex component 7 (24), prostate leucine zipper (25) and hypoxia-inducible factor 1 (26).

Human epidermal growth factor receptor 2 (HER2) is a member of the class I receptor tyrosine kinase family and has substantial homology to epidermal growth factor receptor, HER3 and HER4 (27). HER2 overexpression and/or gene amplification occur in a variety of human epithelial tumors, particularly in breast cancer, in which the receptor and its gene have been investigated extensively (28). Conversely, the significance of HER2 overexpression and gene amplification in PCa remains controversial. Previous studies have used immunohistochemical analysis to evaluate HER2 protein expression in primary prostate specimens, demonstrating expression rates ranging from 0–100% (29–31). Therefore, the exact prevalence of HER2 gene amplifications in primary PCa remains unknown, likely owing to the wide range of antibodies and methods used in these studies (32,33).

The HER2/neu proto-oncogene, which is located on chromosome 17 (OMIM: 164870), encodes a transmembrane tyrosine kinase growth factor receptor (34), whose overexpression was shown to be involved in the development of various types of human cancer, including non-small-cell lung cancer, colon cancer and breast cancer, and may have prognostic value (35,36). Apparent chromosome 17 polysomy, defined by increased chromosome enumeration probe 17 (CEP17) signal number, is a common genetic aberration in breast cancer and represents an alternative mechanism for increasing HER2 copy number (37). However, the prognostic value of HER2/neu amplification in PCa remains controversial (38).

Chromosomal aberrations associated with PCa have been evaluated using various techniques, including classical cytogenetics (39), loss of heterozygosity analysis (40), fluorescence in situ hybridization (FISH) (41) and, most commonly, comparative genomic hybridization (CGH) (42). Although the criteria for amplification have varied between studies, they have implicated several chromosomal regions, such as 6q, 8p, 10q, 13q, 16q and Xq, that may harbor genes involved in the tumorigenesis of PCa (24,43).

The present study aimed to investigate the frequency of HER2 amplification in prostate biopsies from Iranian (Tehran province) patients using chromogenic in situ hybridization (CISH), which permits the rapid analysis of a large number of tumors (44). Although the FISH method has been verified for the histological analysis of tissues, the evaluation of tumor morphology using FISH is challenging and the fluorescence fades quickly (45). These limitations may be overcome by CISH, which enables visualization of the amplification product along with morphological features (46). Furthermore, CISH technology is superior to high-throughput HER2 genetic testing due its speed, although FISH remains the method of choice for rapid low-throughput HER2 genetic testing.

Materials and methods <sec> <title>Clinical specimens

The present study was approved by the Ethics Committee of Tehran University of Medical Sciences (Tehran, Iran). Suitable patients from the oncology wards or outpatient clinics of Imam Khomeini Hospital (Tehran, Iran) were approached for participation in the study, and informed consent was obtained. Inclusion criteria for the study were a PSA level of >4, a diagnosis of progressive prostate cancer, an age of >54 years, a Gleason score of >2 (47) and the male gender. Formalin-fixed, paraffin-embedded (FFPE) specimens were obtained from 32 consecutive PCa patients who underwent surgery between May 2013 and February 2015. Adjacent normal tissue was used as a control. To account for tumor heterogeneity, a minimum of 3 cylindrical core biopsies, 0.6 mm in diameter, were harvested from different regions of each tumor. A total of 15 tissue sections (2-mm thick) were sliced from each paraffin-embedded tumor block and mounted onto glass slides. The first tissue section was stained with hematoxylin and eosin and visualized under a light microscope to ascertain the region of interest. In all cases, a serum sample was measured by Elecsys^® total PSA and free PSA kits (Roche Diagnostics, Basel, Switzerland).

Pathological stage

The stage (extent) of prostate cancer is one of the most important factors in choosing treatment options and predicting prognosis. The stage is based on the prostate biopsy results (including the Gleason score), the blood PSA level at the time of diagnosis, the results of any other exams or tests that were performed to determine metastasis and the pathological stage post-surgery. There are 4 categories for describing the local extent of a prostate tumor, ranging from T1 to T4 (48).

CISH

CISH was performed according to a previously described protocol (49) with minor modifications. Briefly, 2-mm thick archival FFPE tissue sections were deparaffinized and dehydrated in 0.1 mol/l Tris-HCl (pH 7.3) in a temperature-controlled microwave oven at 92°C for 10 min. Subsequently, the sections were allowed to cool for 20 min, followed by washing with phosphate-buffered saline (PBS) for 3–4 min at 37°C. The slides were then dehydrated with graded ethanol, rinsed in saline sodium citrate (pH 7.2) for 5 min at room temperature and air-dried. Enzymatic digestion was performed by incubating the sections with pepsin solution (dilution, 100:l) for 10 to 15 min at room temperature. The slides were then washed with PBS and dehydrated with graded ethanol. The ready-to-use digoxigenin-labeled HER2/neu probe (Zyto Dot 2C SPEC HER2/CEN 17 Probe kit; Zyto Vision GmbH, Bremerhaven, Germany) was applied onto the slides. The presence of certain nucleic acid sequences in cells or tissue can be detected with in situ hybridization using labeled DNA probes. The hybridization results in duplex formation of sequences present in the test object and the specific gene probe. The ZytoDot 2C SPEC HER2/CEN 17 Probe kit uses the ZytoDot 2C SPEC HER2/CEN 17 Probe EmaNOF. The probe contains digoxigenin-labeled polynucleotides, which target sequences of the HER2 gene and DNP-labeled polynucleotides, which target alpha-satellites of the centromere of chromosome 17. Duplex formation of the labeled probe can be visualized using primary (un-marked) antibodies, which are detected by secondary polymerized enzyme-conjugated antibodies. The enzymatic reactions of the substrates leads to the formation of strong permanent red and green signals that can be visualized by light microscopy using a 40X dry lens. The slides were denatured on a hot plate for 3 min and hybridization was performed overnight at 37°C. Following hybridization, the slides were washed with 0.5 ml standard saline citrate for 5 min at 75°C, followed by three washes with PBS containing 0.2% Tween-20 at room temperature. Prostate tissue sections were lightly counterstained with hematoxylin then embedded, and the tissues were analyzed under a light microscope. Amplification was defined when the HER2/chromosome 17 centromere (CEP17) ratio was >2.2.

Statistical analysis

Red/green signals were counted manually. Data analysis was performed using SPSS software version 18 (SPSS, Inc., Chicago, IL, USA). Scale variables were analyzed for normality using the Kolmogorov-Smirnov test. Group comparisons of continuous variables were conducted using the independent-samples t-test. When a variable was non-normally distributed, Mann-Whitney or Kruskal-Wallis non-parametric tests were performed. GraphPad Prism version 5.0 software for Windows (GraphPad Software, La Jolla, CA, USA) was used to illustrate the data through graphs. Data are expressed as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>Associations among age, PSA levels, green/red ratios and Gleason scores in patients with or without HER2 amplification

For statistical analysis, patients were divided into two groups consisting of patients with or without HER2 amplification. Variables were assessed within each group and the results are presented in Tables I–III. The demographic data of patients with PCa with and without HER2 amplification are shown in Table I. There were no associations among the serum levels of PSA, green/red ratios (Fig. 1) or Gleason scores in patients without HER2 amplification.

Amplification levels of the HER2 gene are directly associated with pathological stage in patients with PCa

There was a weak association between the green/red ratio and age in patients without HER2 amplification (P=0.046; Table II), thus suggesting that younger patients exhibited a lower tendency for HER2 amplification. In addition, a positive correlation (P=0.004) was observed between the serum levels of PSA and Gleason score (Table II). The associations between the green/red ratio and PSA levels or Gleason score were not significant (P=0.228 and 0.941, respectively; Table II).

For the analysis, patients were divided into two separate groups based on the level of HER2 gene amplification (i.e., with and without amplification). The first group consisted of 19 patients and the second group consisted of 13 patients. A high level of HER2 gene amplification was considered when the HER2/CEP17 ratio was >2.2 (Fig. 1).

The mean ages were 73.7 and 63.3 years for patients with left- and right-side tumors, respectively, which were not significantly different (P=0.15; Table III). With the exception of the serum levels of PSA (P=0.009), there were no significant differences in any of the parameters (green/red ratio and Gleason score) between patients with left- and right-sided tumors. The mean Gleason score among patients was 5, and the Gleason score showed no association with the pathologic stage (P=0.303; Table III). The tumors were composed of different Gleason scores, but were between stages T2 and T5 (Table III). Similar to the patients without HER2 amplification, there was a significant association between the Gleason score and serum levels of PSA in patients with HER2 amplification (P<0.001; Table IV). However, there was no significant association between the other parameters in patients with HER2 amplification (P>0.05; Table IV). The tumor position was not significantly associated with the mean age, PSA levels, green/red ratio or Gleason score of patients with HER2 amplification, although a significant correlation was observed between the Gleason score and pathologic stage (P=0.002; Table V).

Discussion

DNA ploidy has been accepted as a significant predictor of prognosis in patients with PCa (50). In the present study, amplification and overexpression of HER2 was demonstrated in patients with PCa, which has previously been associated with cancer progression, a poor prognosis and development of androgen independency (51). HER2 status is routinely assigned using in situ hybridization to assess HER2 gene amplification, but interpretation of in situ hybridization results may be challenging in tumors with chromosome 17 polysomy or intratumoral genetic heterogeneity. Apparent chromosome 17 polysomy, defined by increased CEP17 signal number, is a common genetic aberration in breast cancer and represents an alternative mechanism for increasing HER2 copy number. Elevated CEP17 count (polysomy) has been linked with adverse clinicopathologic features and HER2 overexpression, although there are numerous discrepancies in the literature (37). HER2 overexpression and/or amplification are recurrently reported in numerous tumor types, and have been shown to have significant therapeutic implications in patients with cancer (33). A meta-analysis of 5,976 patients demonstrated that HER2/neu overexpression was associated with mortality and recurrence in patients with PCa (52). Furthermore, it has been suggested that HER2 overexpression at the protein level is significantly associated with the amplification of HER2 (53). FISH is considered the gold standard method for detecting gene amplification, and has been reported to be more accurate than flow cytometry and immunohistochemistry (54). An increasing number of authors have employed the CISH method for determining gene amplification in various types of cancer (37,55,56). CISH is a recently developed technique in which the DNA probe is located based on an immunoperoxidase reaction. This method is similar to FISH, although it does not involve the use of fluorescence microscopy. In addition, FISH signals fade within a few weeks and the FISH results must be recorded using expensive digital systems, which is not required for CISH staining. Owing to its resemblance to immunohistochemistry staining (57), CISH is also easier to interpret by pathologists who are not trained in fluorescence microscopy. Furthermore, in previous studies, CISH was observed to be well-correlated with FISH (46,58–60).

The present study used standard CISH to demonstrate that HER2 was amplified in Iranian (Tehran province) patients with PCa. Notably, HER2 amplification was observed in >50% of patients. Similarly, using a FISH technique, a study on 44 patients with PCa demonstrated 53 and 80% low copy amplification in non-metastatic and metastatic samples, respectively (61). The results of the present study were consistent with previous studies, in which HER2 amplification was reported in 44 and 41% of 62 and 113 Americans, respectively, using the FISH method (54,62), whereas another analysis reported no HER2 amplification (63). Furthermore, in a previous study, FFPE tissue blocks from 88 patients demonstrated a minor amplification rate of 9.3% (8/88 cases) (64). Similarly, Qi et al (53) used a FISH method and demonstrated that only 5.8% of Chinese patients with PCa had such a genetic alteration, and an investigation of 93 cancer samples showed that 6.5% had low levels of HER2 amplification, which was co-amplified with the topoisomerase (DNA) II α gene (65). These conflicting results may exist due to variation in the sample size and method used, or as a result of genetic heterogeneity. Furthermore, the findings may suggest that the CISH method is superior to FISH for HER2 detection in PCa samples. CISH has also been utilized for detection of copy number variation in the HER2/neu gene (66). In addition, the accuracy and reproducibility of CISH has been demonstrated in a previous study of breast carcinoma, in which the authors suggested that CISH may be regarded as a practical alternative for FISH (67). Other studies have considered this matter and proposed that CISH is a viable alternative to FISH and had similar properties; for example, both are in situ hybridization techniques and directly visualise the number of gene copies present in the nucleus, but CISH is cheaper and it produces a stable record of the slide that can be interpreted with a light microscope in the background of the tumour histopathology (68). Permanent staining and the absence of a fluorescent dye make CISH a suitable replacement for FISH (69). In addition, its usability, relative inexpensiveness and speed make CISH more attractive than FISH for assessing HER2 amplification/overexpression (59,70).

In conclusion, to the best of our knowledge, the present study is the first to report the amplification of HER2 in Iranian patients (Tehran province) with PCa. Furthermore, it was demonstrated that there were no associations among the serum levels of PSA, green/red ratios or Gleason scores in patients without HER2 amplification. Conversely, there was a weak correlation between the green/red ratio and age in these patients (P=0.046), which suggested the tendency for younger patients to exhibit lower levels of HER2 amplification. Notably, there was no association between the green/red ratio and pathologic stage of patients without HER2 amplification (P=0.873), although the increasing trend suggested that clinicians may consider Herceptin as a drug of choice for patients with PCa. In addition, there was no association between PSA levels (P=0.749) or Gleason score (P=0.057) and pathologic stage in patients without HER2 amplification. In patients with HER2 amplification, there was a significant association between the Gleason score and the serum level of PSA (P<0.001). However, there was no significant association between the other parameters in patients with HER2 amplification (P>0.05). The tumor position was not significantly associated with the mean age, PSA level, green/red ratio or Gleason score of the patients with HER2 amplification, although a significant correlation was observed between the Gleason score and pathological stage (P=0.002; Table V). Finally, the present study confirmed the results of previous studies, which suggested that the CISH method may be considered a valuable replacement for FISH. Further studies involving PCa samples are required in order to validate the results of the present study.

Acknowledgements

The present study was supported by a research grant from Tehran University of Medical Sciences (Tehran, Iran; 516478).

Abbreviations

PCa

prostate cancer

HER2

human epidermal growth factor receptor 2

CISH

chromogenic in situ hybridization

PSA

prostate specific antigen

FISH

florescence in-situ hybridization

References 1

Braga-Basaria

Dobs

Muller

Carducci

John

Egan

Basaria

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

J Clin Oncol24397939832006

10.1200/JCO.2006.05.9741

16921050

Perner

Mosquera

Demichelis

Hofer

Paris

Simko

Collins

Bismar

Chinnaiyan

De Marzo

Rubin

TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion

Am J Surg Pathol318828882007

10.1097/01.pas.0000213424.38503.aa

17527075

Kolahdoozan

Sadjadi

Radmard

Khademi

Five common cancers in Iran

Arch Iran Med131431462010

20187669

Center

Jemal

Lortet-Tieulent

Ward

Ferlay

Brawley

Bray

International variation in prostate cancer incidence and mortality rates

Eur Urol61107910922012

10.1016/j.eururo.2012.02.054

22424666

Wong

Goggins

Wang

Fung

Leung

Wong

Sung

Global incidence and mortality for prostate cancer: Analysis of temporal patterns and trends in 36 countries

Eur UrolJune82016(Epub ahead of print)

10.1016/j.eururo.2016.05.043

Kallioniemi

Visakorpi

Genetic basis and clonal evolution of human prostate cancer

Adv Cancer Res682252551996

10.1016/S0065-230X(08)60355-3

8712069

Boyd

Mao

The complexity of prostate cancer: Genomic alterations and heterogeneity

Nat Rev Urol96526642012

10.1038/nrurol.2012.185

23132303

Heidenreich

Bellmunt

Bolla

Joniau

Mason

Matveev

Mottet

Schmid

van der Kwast

Wiegel

EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease

Eur Urol5961712011

10.1016/j.eururo.2010.10.039

21056534

Damaschke

Yang

Bhusari

Svaren

Jarrard

Epigenetic susceptibility factors for prostate cancer with aging

The Prostate2013731617211730

10.1002/pros.22716

23999928

Parent

Siemiatycki

Occupation and prostate cancer

Epidemiol Rev231381432015

10.1093/oxfordjournals.epirev.a000779

Salmaninejad

Sadeghi

Ghadami

Alterations of KRAS exon 2 codon 12/13 mutation status in prostatic adenocarcinoma; Bioinformatics aspects

Arch Can Res422016

10.21767/2254-6081.100075

Shen

Abate-Shen

Molecular genetics of prostate cancer: New prospects for old challenges

Genes Dev24196720002010

10.1101/gad.1965810

20844012

Eeles

Al Olama

Benlloch

Saunders

Leongamornlert

Tymrakiewicz

Ghoussaini

Luccarini

Dennis

Jugurnauth-Little

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array

Nat Genet45385391391e1-22013

10.1038/ng.2560

23535732

Takata

Akamatsu

Kubo

Takahashi

Hosono

Kawaguchi

Tsunoda

Inazawa

Kamatani

Ogawa

Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population

Nat Genet427517542010

10.1038/ng.635

20676098

Barbieri

Demichelis

Rubin

Molecular genetics of prostate cancer: Emerging appreciation of genetic complexity

Histopathology601871982012

10.1111/j.1365-2559.2011.04041.x

22212086

Tomlins

Laxman

Dhanasekaran

Helgeson

Cao

Morris

Menon

Jing

Cao

Han

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

Nature4485955992007

10.1038/nature06024

17671502

Kumar-Sinha

Tomlins

Chinnaiyan

Recurrent gene fusions in prostate cancer

Nat Rev Cancer84975112008

10.1038/nrc2402

18563191

Santarius

Shipley

Brewer

Stratton

Cooper

A census of amplified and overexpressed human cancer genes

Nat Rev Cancer1059642010

10.1038/nrc2771

20029424

Salmaninejad

Ghadami

Dizaji

Golchehre

Estiar

Zamani

Ebrahimzadeh-Vesal

Nowroozi

Shakoori

Molecular characterization of KRAS, BRAF, and EGFR genes in cases with prostatic adenocarcinoma; reporting bioinformatics description and recurrent mutations

Clin Lab617497592015

26299074

Brown

Edwards

Dogan

Payne

Harland

Bartlett

Masters

Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer

J Pathol1982372442002

10.1002/path.1206

12237884

Saramäki

Tammela

Martikainen

Vessella

Visakorpi

The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer

Genes Chromosomes Cancer456396452006

10.1002/gcc.20327

16575874

Saramäki

Willi

Bratt

Gasser

Koivisto

Nupponen

Bubendorf

Visakorpi

Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer

Am J Pathol159208920942001

10.1016/S0002-9440(10)63060-X

11733359

Bloch

Ousingsawat

Simon

Schraml

Gasser

Mihatsch

Kunzelmann

Bubendorf

KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer

Oncogene26252525342007

10.1038/sj.onc.1210036

17146446

Ren

Tseng

Cieply

Gavel

Nelson

Michalopoulos

Luo

MCM7 amplification and overexpression are associated with prostate cancer progression

Oncogene25109010982006

10.1038/sj.onc.1209134

16247466

Wang

Saramäki

Visakorpi

Sutherland

Zhou

Sen

Lim

Mabjeesh

Amin

PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21. 1 and overexpressed in human prostate cancer

Cancer Res64158915942004

10.1158/0008-5472.CAN-03-3331

14996714

Saramäki

Savinainen

Nupponen

Bratt

Visakorpi

Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer

Cancer Genet Cytogenet12831342001

10.1016/S0165-4608(01)00396-X

11454426

Rimawi

Mayer

Forero

Nanda

Goetz

Rodriguez

Pavlick

Wang

Hilsenbeck

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006

J Clin Oncol31172617312013

10.1200/JCO.2012.44.8027

23569315

Cobleigh

Vogel

Tripathy

Robert

Scholl

Fehrenbacher

Wolter

Paton

Shak

Lieberman

Slamon

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

J Clin Oncol17263926481999

10561337

Poovassery

Kang

Kim

Ober

Ward

Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer

Int J Cancer1372672772015

10.1002/ijc.29378

25471734

Rao

Gaughan

Robson

McCracken

The role of the HER2 and HER3 in prostate cancer and their potential as therapeutic targets

Eur J Cancer61S177S1782016

10.1016/S0959-8049(16)61628-3

Baek

Hong

Jung

Lee

Park

Kim

Yoo

Lee

Correlation of AR, EGFR, and HER2 expression levels in prostate cancer: Immunohistochemical analysis and chromogenic in situ hybridization

Cancer Res Treat4450562012

10.4143/crt.2012.44.1.50

22500161

Reese

Small

Magrane

Waldman

Chew

Sudilovsky

HER2 protein expression and gene amplification in androgen-independent prostate cancer

Am J Clin Pathol1162342392001

10.1309/VXKK-YVRH-9B11-YDPT

11488070

Yan

Schwaederle

Arguello

Millis

Gatalica

Kurzrock

HER2 expression status in diverse cancers: Review of results from 37,992 patients

Cancer Metastasis Rev341571642015

10.1007/s10555-015-9552-6

25712293

Yamanaka

Friess

Kobrin

Büchler

Kunz

Beger

Korc

Overexpression of HER2/neu oncogene in human pancreatic carcinoma

Hum Pathol24112711341993

10.1016/0046-8177(93)90194-L

8104858

Nuciforo

Pellegrini

Fasani

Maggioni

Coggi

Parafioriti

Bosari

Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma

Hum Pathol346396452003

10.1016/S0046-8177(03)00238-7

12874758

Salmaninejad

Estiar

Gill

Shih

Hewitt

Jeon

Fukuoka

Shilo

Shakoori

Jen

Expression analysis of p16, c-Myc, and mSin3A in non-small cell lung cancer by computer aided scoring and analysis (CASA)

Clin Lab615495592015

26118188

Hanna

Rüschoff

Bilous

Coudry

Dowsett

Osamura

Penault-Llorca

van de Vijver

Viale

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Mod Pathol274182014

10.1038/modpathol.2013.103

23807776

Bar-Shira

Pinthus

Rozovsky

Goldstein

Sellers

Yaron

Eshhar

Orr-Urtreger

Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft

Cancer Res62680368072002

12460888

Sattler

Lensch

Rohde

Zimmer

Meese

Bonkhoff

Retz

Zwergel

Bex

Stoeckle

Wullich

Novel amplification unit at chromosome 3q25-q27 in human prostate cancer

Prostate452072152000

10.1002/1097-0045(20001101)45:3<207::AID-PROS2>3.0.CO;2-H

11074522

Elo

Visakorpi

Molecular genetics of prostate cancer

Ann Med331301412001

10.3109/07853890109002068

11327116

Edwards

Mukherjee

Munro

Wells

Almushatat

Bartlett

HER2 and COX2 expression in human prostate cancer

Eur J Cancer4050552004

10.1016/j.ejca.2003.08.010

14687789

Edwards

Krishna

Witton

Bartlett

Gene amplifications associated with the development of hormone-resistant prostate cancer

Clin Cancer Res9527125812003

14614009

Nupponen

Kakkola

Koivisto

Visakorpi

Genetic alterations in hormone-refractory recurrent prostate carcinomas

Am J Pathol1531411481998

10.1016/S0002-9440(10)65554-X

9665474

Lass

Hartmann

Capper

Herold-Mende

von Deimling

Meiboom

Mueller

Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas

Brain Pathol233113182013

10.1111/bpa.12003

23107103

Zhang

Perez

Blondin

Liu

Escarzaga

Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment

BMC Cancer141292014

10.1186/1471-2407-14-129

24568597

Arnould

Denoux

MacGrogan

Penault-Llorca

Fiche

Treilleux

Mathieu

Vincent-Salomon

Vilain

Couturier

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

Br J Cancer88158715912003

10.1038/sj.bjc.6600943

12771927

Brimo

Montironi

Egevad

Erbersdobler

Lin

Nelson

Rubin

van der Kwast

Amin

Epstein

Contemporary grading for prostate cancer: Implications for patient care

Eur Urol638929012013

10.1016/j.eururo.2012.10.015

23092544

Heidenreich

Bastian

Bellmunt

Bolla

Joniau

van der Kwast

Mason

Matveev

Wiegel

Zattoni

Mottet

European Association of Urology: EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent - update 2013

Eur Urol651241372014

10.1016/j.eururo.2013.09.046

24207135

Tanner

Gancberg

Di Leo

Larsimont

Rouas

Piccart

Isola

Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

Am J Pathol157146714722000

10.1016/S0002-9440(10)64785-2

11073807

Lennartz

Minner

Brasch

Wittmann

Paterna

Angermeier

Öztürk

Shihada

Ruge

Kluth

The combination of DNA ploidy status and PTEN/6q15 deletions provides strong and independent prognostic information in prostate cancer

Clin Cancer Res22280228112016

10.1158/1078-0432.CCR-15-0635

26813356

Di Lorenzo

Tortora

D'Armiento

De Rosa

Staibano

Autorino

D'Armiento

De Laurentiis

De Placido

Catalano

Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer

Clin Cancer Res8343834442002

12429632

Neto

Tobias-Machado

Wroclawski

Fonseca

Teixeira

Amarante

Wroclawski

Del Giglio

Her-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis

J Urol1848428502010

10.1016/j.juro.2010.04.077

20663525

Yang

Zhang

Lin

Sun

Yuan

Ren

Zhang

Qin

Han

ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients

PLoS One9e849592014

10.1371/journal.pone.0084959

24516518

Ross

Sheehan

Hayner-Buchan

Ambros

Kallakury

Kaufman

Fisher

Muraca

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization

Hum Pathol288278331997

10.1016/S0046-8177(97)90157-X

9224752

Valtorta

Misale

Sartore-Bianchi

Nagtegaal

Paraf

Lauricella

Dimartino

Hobor

Jacobs

Ercolani

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

Int J Cancer133125912652013

10.1002/ijc.28106

23404247

Park

Hwang

Park

Ryu

M-H

Chang

H-M

Yook

Kim

Jang

Kang

Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: Which scoring system should we use?

Hum Pathol434134222012

10.1016/j.humpath.2011.05.019

21855114

Jacquemier

Spyratos

Esterni

Mozziconacci

M-J

Antoine

Arnould

Lizard

Bertheau

Lehmann-Che

Fournier

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: A multicenter experience based on 840 cases

BMC Cancer133512013

10.1186/1471-2407-13-351

23875536

Horii

Matsuura

Iwase

Ito

Akiyama

Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer

Breast Cancer215986042014

10.1007/s12282-012-0436-0

23307494

Rosa

Santos

Rogatto

Domingues

Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas

Braz J Med Biol Res462072162013

10.1590/1414-431X20132483

23558859

Kiyose

Igarashi

Nagura

Kamo

Kawane

Mori

Ozawa

Maeda

Konno

Hoshino

Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)

Pathol Int627287342012

10.1111/j.1440-1827.2012.02862.x

23121603

Liu

Gandour-Edwards

Lara

Jrde Vere White

LaSalle

Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization

Cancer J73954032001

11693898

Ross

Sheehan

Hayner-Buchan

Ambros

Kallakury

Kaufman

JrFisher

Rifkin

Muraca

Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma

Cancer79216221701997

10.1002/(SICI)1097-0142(19970601)79:11<2162::AID-CNCR14>3.0.CO;2-U

9179063

Sadasivan

Morgan

Jennings

Austenfeld

Van Veldhuizen

Stephens

Noble

Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer

J Urol1501261311993

7685420

Mark

Feldman

Das

Kye

Mark

Sun

Samy

Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer

Exp Mol Pathol661701781999

10.1006/exmp.1999.2242

10409446

Murphy

Hughes

Barrett

Magee

Loftus

O'Leary

Sheils

Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival

Cancer Res67289328982007

10.1158/0008-5472.CAN-06-2962

17363613

Savinainen

Saramäki

Linja

Bratt

Tammela

Isola

Visakorpi

Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer

Am J Pathol1603393452002

10.1016/S0002-9440(10)64377-5

11786427

Loring

Cummins

O'Grady

Kay

HER2 positivity in breast carcinoma: A comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization

Appl Immunohistochem Mol Morphol131942002005

10.1097/01.pai.0000132189.01233.6d

15894935

van de Vijver

Bilous

Hanna

Hofmann

Kristel

Penault-Llorca

Rüschoff

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: An international validation ring study

Breast Cancer Res9R682007

10.1186/bcr1776

17922920

Elliott

Hamilton

Maxwell

Fluorescence (FISH) and chromogenic (CISH) in situ hybridisation in prostate carcinoma cell lines: Comparison and use of virtual microscopy

Br J Biomed Sci651671712008

10.1080/09674845.2008.11732823

19181033

Penault-Llorca

Bilous

Dowsett

Hanna

Osamura

Rüschoff

van de Vijver

Emerging technologies for assessing HER2 amplification

Am J Clin Pathol1325395482009

10.1309/AJCPV2I0HGPMGBSQ

19762531

Figure 1.

Human epidermal growth factor receptor 2/neu oncogene gene status in prostate carcinomas, as detected by chromogenic in situ hybridization. Green signals correspond to HER2, and red signals correspond to (magnification, ×100). (A) HER2 gene non-amplified. (B) HER2 gene amplified. A high level of HER2 gene amplification was detected when the HER2/CEP17 ratio was >2.2. HER2, human epidermal growth factor receptor 2; CEP17, chromosome 17 centromere.

Table I.

Prostate cancer patients with or without HER2 amplification.

Patient ID	Age	Situation	PSA	Pathologic grade	Gleason score	Green signal	Red signal	Green/red
P-709	55	L	5.1	2	4	271	116	2.31
P-436	82	R	8.1	3b	5	410	134	3.05
P-1139	56	L	8.2	2	4	201	83	2.42
P-100	65	L	9.2	3a		355	130	2.73
P-326	61	L	9.3	4b	6	296	90	3.28
P-435	82	R	6.1	3a	5	168	75	2.24
P-1101	67	R	195	4b	7	401	134	2.99
P-564	66	L	10.9	3a	6	201	68	2.95
P-62	69	L	32.8	3a	5	278	116	2.39
P-27	83	L	9.3	3a	5	180	71	2.53
P-63	61	R	14.8	3a	5	214	95	2.25
P-425	82	L	16.2	3a	5	220	75	2.93
P-599	75	R	74.3	4b	7	224	88	2.54
P-13	83	R	16.4	4b	6	485	181	2.67
P-68	70	L	156.2	4b	7	182	73	2.49
P-80	70	R	9.2	4	6	465	193	2.41
P-69	66	L	19.2	4	7	459	186	2.46
P-137	78	R	20.8	4	6	150	68	2.22
P-162	75	L	33.1	4	6	421	166	2.53
P-691	65	L	4.95	2	4	444	256	1.73
P-993	61	L	69.8	4b	8	212	165	1.28
P-1084	82	L	45.7	4a	7	–	–	–
P-806	78	L	6.1	4b	7	229	112	2.04
P-856	80	L	78.3	4a	6	240	123	1.95
P-27	83	L	8.1	3a	5	221	110	2.00
P-150	68	R	8.9	4b	6	–	120	–
P-439	82	L	6.1	3a	5	160	79	2.02
P-174	57	R	5.5	2	4	112	60	1.80
P-12	71	L	18.6	3c	5	478	233	2.05
P-37	77	L	140.1	4	6	110	59	1.86
P-83	58	L	7.3	4	5	165	86	1.91
P-164	74	R	4.4	4	5	596	281	2.12

HER2 amplification was considered when the green/red ratio was >2.2. HER2, human epidermal growth factor receptor 2; PSA, prostate-specific antigen; L, left; R, right.

Table II.

P-values for the associations between the mean age, serum levels of PSA, green/red ratio and Gleason score of patients without human epidermal growth factor receptor 2 amplification.

Parameter	Age	PSA	Green/red	Gleason
Age	–	0.23	0.046	0.253
PSA	–	–	0.228	0.004
Green/red	–	–	–	0.941

PSA, prostate-specific antigen.

Table III.

Associations among tumor position, pathological stage, age, serum levels of PSA, green/red ratio and Gleason score in patients without human epidermal growth factor receptor 2 amplification.

Parameter	Age	PSA	Green/red	Gleason score
Tumor position
Left	73.7±9.3	38.4±45.2	1.88±0.23	5.8±1.2
Right	66.33±8.61	6.1±2.5	1.97±0.16	5±1
P-value	0.15	0.009	0.453	0.240
Pathologic stage
2	61±5.6	5.22±0.38	4	1.76
3a	82±0.70	7±1.41	2	5
3c	71	18.6	2.05	5
4	69.66±10.21	50.43±77.58	1.96±0.14	5.33±0.5
4a	81±0.71	62±23.05	1.95	6±0.71
4b	69±8.54	28.27±36.00	1.66±0.54	7±1
P-value	0.142	0.749	0.873	0.057

Data are presented as the mean ± standard deviation. PSA, prostate-specific antigen.

Table IV.

P-values for the associations between the age, serum levels of PSA, green/red ratio and Gleason score of patients with human epidermal growth factor receptor 2 amplification.

Parameter	Age	PSA	Green/red	Gleason
Age	–	0.248	0.571	0.522
PSA	–	–	0.404	<0.001^a
Green/red	–	–	–	0.62

Correlation is significant at the 0.01 level (two-tailed). PSA, prostate-specific antigen.

Table V.

Associations among tumor position, pathologic stage, age, serum levels of PSA, green/red ratio and Gleason score in patients with human epidermal growth factor receptor 2 amplification.

Parameter	Age	PSA	Green/red	Gleason score
Tumor position
Left	68.0±9.24	28.4±43.5	2.64±0.3	5.5±1.0
Right	74.75±8.0	43±65.25	2.55±0.33	5.89±0.83
P-value	0.75	0.643	0.382	0.290
Pathologic stage
2	55.5±0.71	6.55±2	2.36±0.08	4
3a	73.83±9.67	15±9.45	2.58±0.3	5.17±0.4
3b	82	8	3.05	5
4a	72.25±5.32	20.55±9.7	2.4±0.15	6.25±0.5
4b	71.2±8.32	90.24±83.04	2.79±0.33	6.6±0.55
P-value	0.095	0.078	0.123	0.002

Data are presented as the mean ± standard deviation. PSA, prostate-specific antigen.